Xue Bo Zeng
Direttore/Membro del Consiglio presso SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Profilo
Xue Bo Zeng is currently the Director at Chiral Quest (Suzhou) Co., Ltd., Director at Shanghai Model Organisms Center, Inc., Director at Hangzhou Sciwind Biosciences Co., Ltd., Non-Executive Director at Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Executive Director at IDG Capital, Director at Shandong Bestcomm Pharmaceutical Co., Ltd., Independent Director at CASI Pharmaceuticals, Inc., and Vice President at Hexie Zhuorui Zhuhai Investment Management Co. Ltd.
Mr. Zeng previously worked as Deputy Director at Shenzhen Investment Holdings Co., Ltd.
Mr. Zeng obtained an undergraduate degree from Qinghai Nationalities University in 2009.
Posizioni attive di Xue Bo Zeng
Società | Posizione | Inizio |
---|---|---|
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Direttore/Membro del Consiglio | 30/07/2022 |
CASI PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 21/03/2023 |
SHANGHAI MODEL ORGANISMS CENTER, INC. | Direttore/Membro del Consiglio | 01/09/2022 |
IDG Capital | Direttore/Membro del Consiglio | 01/01/2016 |
Hexie Zhuorui Zhuhai Investment Management Co. Ltd. | Corporate Officer/Principal | 01/11/2020 |
Shandong Bestcomm Pharmaceutical Co., Ltd.
Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China. | Direttore/Membro del Consiglio | 01/12/2017 |
Hangzhou Sciwind Biosciences Co., Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Direttore/Membro del Consiglio | - |
Chiral Quest (Suzhou) Co., Ltd.
Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Xue Bo Zeng
Società | Posizione | Fine |
---|---|---|
Shenzhen Investment Holdings Co., Ltd.
Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Corporate Officer/Principal | 01/07/2016 |
Formazione di Xue Bo Zeng
Qinghai Nationalities University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
SHANGHAI MODEL ORGANISMS CENTER, INC. | Commercial Services |
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Health Technology |
CASI PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Chiral Quest (Suzhou) Co., Ltd.
Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Commercial Services |
Shenzhen Investment Holdings Co., Ltd.
Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Finance |
Shandong Bestcomm Pharmaceutical Co., Ltd.
Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China. | Commercial Services |
Hangzhou Sciwind Biosciences Co., Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Health Technology |
IDG Capital | |
Hexie Zhuorui Zhuhai Investment Management Co. Ltd. |
- Borsa valori
- Insiders
- Xue Bo Zeng